Učitavanje...
ACTR-29. A PHASE 2 STUDY OF TTFIELDS AND PULSED BEVACIZUMAB IN PATIENTS WITH BEVACIZUMAB-REFRACTORY RECURRENT GLIOBLASTOMA
Despite aggressive treatment comprising surgery, radiation therapy and chemotherapy, the median overall survival (OS) for patients with recurrent GBM averages 25 weeks. Our prior experience in 8 bevacizumab-refractory GBM patients initially treated with TTFields monotherapy and re-challenged with be...
Spremljeno u:
| Izdano u: | Neuro Oncol |
|---|---|
| Glavni autori: | , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Oxford University Press
2017
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5692742/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.024 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|